Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Herder

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
JAMA Internal Medicine|July 5, 2018
Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or RejectedMatthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 24, 2015
Reinstitutionalizing transparency at Health CanadaMatthew Herder
The Milbank Quarterly|August 14, 2019
Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional IncumbencyMatthew Herder
Annals of Health Law|September 29, 2011
Patents & the progress of personalized medicine: biomarkers research as lensMatthew Herder
Nature Medicine|August 8, 2014
Government regulators must steward drug transparencyMatthew Herder
Journal of Law and the Biosciences|October 25, 2016
Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and CanadaMatthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 31, 2011
Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial resultsMatthew Herder
Plos Medicine|January 4, 2017
What Is the Purpose of the Orphan Drug Act?Matthew Herder
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 13, 2024
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural ReformMatthew Herder
Health Law Review|March 3, 2005
Donate a definitionMatthew Herder
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
JAMA Internal Medicine|July 5, 2018
Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or RejectedMatthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 24, 2015
Reinstitutionalizing transparency at Health CanadaMatthew Herder
The Milbank Quarterly|August 14, 2019
Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional IncumbencyMatthew Herder
Annals of Health Law|September 29, 2011
Patents & the progress of personalized medicine: biomarkers research as lensMatthew Herder
Nature Medicine|August 8, 2014
Government regulators must steward drug transparencyMatthew Herder
Journal of Law and the Biosciences|October 25, 2016
Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and CanadaMatthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 31, 2011
Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial resultsMatthew Herder
Plos Medicine|January 4, 2017
What Is the Purpose of the Orphan Drug Act?Matthew Herder
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 13, 2024
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural ReformMatthew Herder
Health Law Review|March 3, 2005
Donate a definitionMatthew Herder
Pageof 6